Adjusting starting points for initial price offers: the example of ibrutinib

This article focuses on the data obtained for ibrutinib, an oral medication for treating hematologic malignancies, which is one of the only drugs reviewed by the committee that also has been selected for Medicare price negotiation. We examine data that can be obtained only from the drug manufacturer that the IRA has explicitly identified as being used to determine the price and suggest potential negotiation strategies for CMS in response.PMID:38603534 | DOI:10.37765/ajmc.2024.89531
Source: The American Journal of Managed Care - Category: Health Management Authors: Source Type: research